Search for a trial | Research with human participants

1 results

A randomized, open label study comparing safety and efficacy parameters for a high and a low dose of ambrisentan (adjusted for body weight) for the treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years (AMB112529)

Approved WMOWill not start

Primary: Safety and tolerability of 2 dosages of ambrisentan. Secundary: Efficacy and PK.